Abstracts tagged "Pediatric rheumatology"

Abstract Number: 0117 • ACR Convergence 2024
Validation of the 2023 American College of Rheumatology/European League Against Rheumatism Antiphospholipid Syndrome Classification Criteria in the Pediatric Population
Daniel Bar¹, Stanley Niznik², Shiri Spielman³, Rotem Semo-Oz⁴, Assaf Barg³, Sarina Levy-Mendelovich³, Gili Kenet², Nancy Agmon- Levin² and Irit Tirosh⁵, ¹Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Herzliya, HaMerkaz, Israel, ²Sheba Medical Center, Tel Aviv, Israel, ³Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Tel Aviv, Israel, ⁴Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Herzliya, Israel, ⁵Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Savyon, Israel
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous or microvascular thrombosis, obstetric morbidity and/or non-thrombotic manifestations. The 2023 ACR/EULAR APS…
Abstract Number: 0395 • ACR Convergence 2024
Assessment of Enthesitis by Pediatric Rheumatology Providers
Erin Treemarcki¹, Shirley Tse², Marisa Klein-Gitelman³, Adam Mayer⁴, Hemalatha Srinivasalu⁵, Heather Walters⁶ and Melissa Oliver⁷, and the CARRA Juvenile Spondyloarthritis Workgroup and the CARRA investigators, ¹University of Utah, Salt Lake City, UT, ²SickKids, Toronto, ON, Canada, ³Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Children's National Hospital, Washington, DC, ⁶Northwell Health, New Hyde Park, NY, ⁷Indiana University, Indianapolis, IN
Background/Purpose: Enthesitis is a characteristic feature of enthesitis related arthritis (ERA) but can be found in other juvenile idiopathic arthritis (JIA) subtypes. It occurs with…
Abstract Number: 0830 • ACR Convergence 2024
Activation of Autoreactive Lymphocytes in the Lung by STING Gain-of-function Mutation Expressing Radioresistant Cells
Kevin Gao¹, Kristy Chiang¹, Sharon Subramanian¹, Xihui Yin², Paul Utz³, Kerstin Nundel¹, Katherine A. Fitzgerald⁴ and Ann Marshak-Rothstein¹, ¹UMass Chan Medical School, Worcester, MA, ²Stanford University School of Medicine, Palo Alto, CA, ³Stanford University, Stanford, CA, ⁴UMass Chan Medical School, Worchester, MA
Background/Purpose: Gain-of-function mutations in STING, a critical mediator of dsDNA sensing, lead to a severe autoinflammatory syndrome known as STING-Associated Vasculopathy with onset in Infancy…
Abstract Number: 1263 • ACR Convergence 2024
Assessing Lupus Low Disease Activity State in the Pediatric Rheumatology Clinic: Baseline Data Collection from a Pediatric Lupus Collaborative
Emily Smitherman¹, Julia Harris², Aimee Hersh³, Jennifer Huggins⁴, Ashley Lytch⁵, Hanh Ho⁶, Ashley Meyer⁷, Megan Quinlan-Waters⁴, Livie Timmerman⁸ and Jon Burnham⁹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Children's Mercy Kansas City, Overland Park, KS, ³University of Utah, Salt Lake City, UT, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Children's Mercy Hospital, Kansas City, MO, ⁶Children's Mercy Kansas City, Kansas City, ⁷Children's Hospital of Philadelphia, Philadelphia, ⁸University of Alabama at Birmingham, Gardendale, AL, ⁹Children's Hospital of Philadelphia, Bryn Mawr, PA
Background/Purpose: Achievement of a lupus low disease activity state (LLDAS) has been associated with less organ damage, fewer disease flares, and improved health-related quality of…
Abstract Number: 1281 • ACR Convergence 2024
The Brazilian Registry of Juvenile Dermatomyositis: Relationship Between Ultraviolet Radiation and Laboratory Markers of Juvenile Dermatomyositis in a Tropical Country
Beatriz Carneiro¹, Adriana Elias², Claudia Saad-Magalhaes³, Erick Kill², Sylvia Farhat², Teresa Robazzi⁴, Ana Julia Moraes⁵, Sheila Oliveira⁶, Luciana Carvalho⁷, Taciana Fernandes³, Carlos Rabello⁸, Maria Teresa Terreri⁹, Silvana Sacchetti¹⁰, Simone Appenzeller¹¹, Clovis Silva¹², Claudio Len¹³, Darcisio Antonio¹⁴, Iloite Scheibel¹⁵, Melissa Fraga¹⁶, Marcia Bandeira¹⁷, Andre Cavalcante¹⁸, Ana Paula Vecchi¹⁹, Roberto Marini²⁰, Flavio Sztajnbok²¹, Nadia Aikawa²², lucia Maria Campos², Katia Kozu² and Maria Paula Ribeiro², ¹University of São Paulo, São Paulo, SP, Brazil, ²University of Sao Paulo, São Paulo, SP, ³São Paulo State University, Botucatu, ⁴University of Bahia, Salvador, ⁵Para Federal University, Belém do Pará, ⁶Rio de Janeiro Federal University, Rio de Janeiro, Brazil, ⁷University of São Paulo (Ribeirao Preto), Ribeirao Preto, ⁸Albert Sabin Children's Hospital, Fortaleza, ⁹UNIFESP, São Paulo, SP, Brazil, ¹⁰Santa Casa Medical School, São Paulo, SP, Brazil, ¹¹Unicamp, Campinas, SP, Brazil, ¹²Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ¹³Federal University of Sao Paulo, São Paulo, SP, ¹⁴São Paulo State University, Botucatu, SP, Brazil, ¹⁵Conceição's Hospital of Porto Alegre, Porto Alegre, ¹⁶Universidade Federal de São Paulo, São Paulo, SP, Brazil, ¹⁷Pequeno Principe Hospital, Curitiba, ¹⁸Pernambuco Federal University, Recife, ¹⁹Children's Hospital of Goiania, Goiânia, ²⁰Campinas State University, Campinas, ²¹UFRJ/UERJ, SAO PAULO, Brazil, ²²Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
Background/Purpose: Ultraviolet (UV) waves are risk factors for juvenile dermatomyositis (JDM), when compared to other types of myositis without skin involvement. Patients with JDM have…
Abstract Number: 1766 • ACR Convergence 2024
STAT2-Associated Type I Interferonopathy: A Masquerade of Infectious Susceptibility
Conor Gruber¹, Angelica Lee², Sofija Buta², Marta Martin Fernandez², Veronique Houdouin³, Jean-Laurent Casanova⁴, Alice Hadchouel⁵, Jacinta Bustamante⁵ and Dusan Bogunovic², ¹Mount Sinai Hospital, New York, NY, ²Columbia University, New York, NY, ³Robert Debré Hospital, Paris, France, ⁴Rockefeller University, New York, NY, ⁵Hôpital Necker-Enfants Malades, Paris, France
Background/Purpose: Type I IFN (IFN-I) signaling is a potent inflammatory pathway fundamental to antiviral immunity. In humans, loss of IFN-I activity underlies severe viral disease,…
Abstract Number: 1925 • ACR Convergence 2024
Use of Geocoded Social Deprivation Indices to Understand Health Disparities in Pediatric Rheumatology
William Soulsby and Emily Von Scheven, University of California, San Francisco, San Francisco, CA
Background/Purpose: Social determinants of health (SDoH) may impact health outcomes via neighborhood-level factors, such as access to medical care and neighborhood safety. Therefore, geocoded measures…
Abstract Number: 2187 • ACR Convergence 2024
Outcomes Following Tonsillectomy in Children with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome
Kalpana Manthiram¹, Ana Ortega-Villa², Sivia Lapidus³, Mary Bowes², Tina Romeo⁴, Kathryn Garguilo⁵, Laura Failla², Hemalatha Srinivasalu⁶, Pamela Mudd⁷, Roberta DeBiasi⁸, Amanda Ombrello⁹, Karyl Barron¹⁰, Daniel Kastner¹¹ and Kathryn Edwards⁵, ¹National Institute of Allergy and Infectious Disease, Bethesda, MD, ²National Institute of Allergy and Infectious Diseases, Bethesda, MD, ³Hackensack University Medical Center, Montclair, NJ, ⁴NIH, Bethesda, MD, ⁵Vanderbilt University School of Medicine, Nashville, TN, ⁶Children's National Hospital, Washington, DC, ⁷Children's National Hospital, Washington, ⁸Children's National Hospital and Research Institute, Washington, DC, ⁹National Institutes of Health, Rockville, MD, ¹⁰NIAID, NIH, Bethesda, MD, ¹¹National Human Genome Research Institute, Bethesda, MD
Background/Purpose: Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome is the most common periodic fever syndrome in children. Tonsillectomy leads to cessation of…
Abstract Number: 2205 • ACR Convergence 2024
Presence of Nailfold Capillary Changes Correlates with More Severe Organ Involvement in Juvenile Systemic Scleroderma. Results of the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Kathryn Torok³, Ozgur Kasapcopur⁴, Amra Adrovic⁵, Brian Feldman⁶, Jordi Anton⁷, Sindhu R. Johnson⁸, Flavio Sztajnbok⁹, Maria Teresa Terreri¹⁰, Ana Sakamoto¹¹, Valda Stanevica¹², Dieneke Schonenberg-Meinema¹³, Ekaterina Alexeeva¹⁴, Maria Katsicas¹⁵, Raju Khubchandani¹⁶, Sujata Sawhney¹⁷, vanessa smith¹⁸, Eslam Al-Abadi¹⁹, Simone Appenzeller²⁰, Tadey Avcin²¹, Mikhail Kostik²², Thomas Lehman²³, Hana Malcova²⁴, edoardo marrani²⁵, Clare Pain²⁶, Anjali Patwardhan²⁷, Walter Alberto Sifuentes-Giraldo²⁸, Natalia Vasquez-Canizares²⁹, Sima Abu Alsaoud³⁰, Patricia Costa Reis³¹, Mahesh Janarthanan³², Dana Nemcova³³, Maria Jose Santos³⁴ and Nicola Helmus³⁵, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁵Cerrahpasa Medical School, Istanbul, Turkey, ⁶Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁷Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁸University of Toronto, Toronto, Canada, ⁹UFRJ/UERJ, SAO PAULO, Brazil, ¹⁰UNIFESP, São Paulo, SP, Brazil, ¹¹Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil, ¹²Childrens Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹³Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁴National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ¹⁵Hospital Garrahan, Buenos Aires, Argentina, ¹⁶SRCC Childrens Hospital, Mumbai, India, ¹⁷Sir Ganga Ram Hospital, Sector 37 noida, Uttar Pradesh, India, ¹⁸Ghent University Hospital, Gent, Belgium, ¹⁹Birmingham Women’s and Children’s Hospital NHSFT, Birmingham, United Kingdom, ²⁰Unicamp, Campinas, SP, Brazil, ²¹University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²²Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²³Hospital for Special Surgery, New York, NY, ²⁴Motol University Hospital, Prague, Czech Republic, ²⁵Dipartimento Neurofarba, Università di Firenze, Firenze, Italy, ²⁶Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom, ²⁷University of Missouri-Columbia, Department of Child Health, 404 N Keene Street, Columbia MO 65210, Columbia, ²⁸Hospital Universitario Ramon y Cajal, Madrid, Spain, ²⁹Children’s Hospital at Montefiore, Bronx, NY, ³⁰Caritas baby Hospital, East Jerusalem, Israel, ³¹Hospital de Santa Maria, Lisbon, Portugal, ³²SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, Tamil Nadu, India, ³³MD, Prague, Czech Republic, ³⁴Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ³⁵Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic scleroderma (jSSc) is an orphan disease with a prevalence in 3 in 1 000 000 children. Positive nailfold capillaroscopy (NF+) finding correlate with more…
Abstract Number: 2622 • ACR Convergence 2024
Quality of Care for Childhood-Onset Lupus Nephritis: Suboptimal Completion of Disease Activity Monitoring
Emily Smitherman¹, Justin Leach¹, Aimee Hersh², Melissa Mannion¹, Jinoos Yazdany³ and Jeffrey Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³UCSF, San Francisco, CA, ⁴University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Poorly controlled childhood-onset lupus nephritis (cLN) can lead to end-stage kidney disease (ESKD), requiring kidney replacement therapies with substantial financial and quality of life…
Abstract Number: 0183 • ACR Convergence 2024
Sensitivity of 2019 EULAR/ACR SLE Criteria and Initial Organ Manifestations for Black and Hispanic Children with Juvenile Systemic Lupus Erythematosus (jSLE) at a Large Tertiary Care Center
Michelle Butts¹, Emily Beil¹, Danielle Guffey², Andrea Ramirez¹, Cagri Yildirim-Toruner³, Erin Peckham-Gregory¹ and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disorder with diverse features, posing classification challenges. In 2019, EULAR and ACR developed new classification criteria to…
Abstract Number: 0396 • ACR Convergence 2024
Inflammatory Markers of Autoimmune Uveitis in the Eye, Tears and Blood
Maryrose Hahn¹, Madison Mangin², Kellen Winden³, Pui Lee⁴, Mindy Lo², Bharti Nihalani-Gangwani², Yasmin Massoudi⁵, Tate Valerio⁵, Amanda Colombo⁵, Jessica Scott⁶, Stephen Anesi⁶, C. Stephen Foster⁶, Peter Nigrovic⁷, sheila Angeles-Han⁸, Peter Chang⁶ and Margaret Chang², ¹Boston Children's Hospital, Georgetown, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Boston Children's Hospital, Newton, MA, ⁵Massachusetts Eye Research and Surgery Institution, Waltham, MA, ⁶Massachusetts Eye Research and Surgery Institution, Waltham, ⁷Boston Children's Hospital, Brookline, MA, ⁸Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Autoimmune uveitis is an inflammatory disorder of the eye that is associated with significant morbidity, including vision-threatening complications and chronic reliance on immunosuppressive therapies.…
Abstract Number: 0831 • ACR Convergence 2024
JDM Proteomic Signature at Disease Onset and Progression Highlights Persistent Dysregulation of Cell Death, Redox and Innate Immune Signaling
Jessica Neely¹, Jeff Dvergsten², Zilan Zheng¹, Chioma Madubata³, Hanna Kim⁴, Sara Sabbagh⁵, Sophia Matossian⁶, Christine Goudsmit⁶, Celine Berthier⁶ and Jessica Turnier⁷, and for the CARRA Registry Investigators and Translational Medicine for Juvenile Myositis Working Group, ¹UCSF, San Francisco, CA, ²Duke University Hospital, Hillsborough, NC, ³University of California, San Francisco, San Francisco, CA, ⁴National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) patients frequently have incomplete response to therapy. We utilized exploratory proteomics to advance understanding of dysregulated proteins and biological pathways that…
Abstract Number: 1264 • ACR Convergence 2024
Improving Mental Health Care for Youth with Juvenile Dermatomyositis Through Integration of Mental Health Screening into Pediatric Rheumatology Clinic
Emily Datyner, Lisa Buckley, Brittany Nelson and Alaina Davis, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN
Background/Purpose: The negative impact of juvenile dermatomyositis (JDM) on emotional health is well-recognized. Barriers to appropriate mental health treatment include limited availability of providers and…
Abstract Number: 1282 • ACR Convergence 2024
Investigating the Genetics of Depression and Anxiety in Children and Adolescents with and Without Systemic Lupus Erythematosus
Indrani Das¹, Nicholas Gold², Christie Burton¹, Jennifer Crosbie¹, JingJing Cao¹, Daniela Dominguez¹, Sefi Kronenberg³, Lawrence Ng², Alene Toulany¹, Hiu-Ki Rachel Tran¹, Gwyneth Zai⁴, Andrea Knight⁵ and Linda Hiraki², ¹The Hospital for Sick Children, Toronto, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Holland-Bloorview Kids Rehabilitation Hospital., Toronto, Canada, ⁴Centre for Addiction and Mental Health, Toronto, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) have a higher prevalence of depression and anxiety compared to healthy peers. Patients with cSLE also have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.